Lilly Licenses Merck KGaA Insomnia Agent EMD 281014
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase I 5-HT2a antagonist also has potential for use in other central nervous system disorders, Lilly says. Possible benefits in sleep category include less next-day side effects and use in broad patient population.
You may also be interested in...
Arena Will Move 5-HT2A Antagonist Into Phase III For Insomnia In 2008
Phase II data show that APD125 significantly improves sleep maintenance in chronic insomnia patients.
Arena Will Move 5-HT2A Antagonist Into Phase III For Insomnia In 2008
Phase II data show that APD125 significantly improves sleep maintenance in chronic insomnia patients.
Pfizer/Neurocrine File First Indiplon NDA With Eye On Q4 2005 Launch
The first of two NDA filings for Pfizer/Neurocrine's insomnia agent indiplon puts the drug on track for a launch in the fourth quarter of 2005